Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cavrotolimod
- Development stage
- Phase 1
- Lead developer
- BlueJay Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral, Subcutaneous
01
Overview
Cavrotolimod is a synthetic spherical nucleic acid (SNA) designed as an agonist of Toll-like receptor 9 (TLR9). It acts as a potent innate immune activator, specifically stimulating Th1-type immune responses by targeting and activating TLR9 within endosomes of various immune cells, including monocytes/macrophages, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells, and B cells. Cavrotolimod is being developed primarily for the treatment of solid tumors such as advanced Merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (CSCC), and chronic hepatitis B virus infection. The drug has demonstrated anti-tumor effects in preclinical models and early-phase clinical trials by inducing cytokine production, enhancing antigen-presenting cell activity, and promoting both innate and adaptive immune responses. Cavrotolimod was originally developed by Exicure but is now being advanced by Bluejay Therapeutics.
- Other names
- cavrotolimod
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on cavrotolimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cavrotolimod.